CPR-SRP 03.03.05 - accordo: bilbiografia


(Conferenza permanente per i rapporti tra lo stato le regioni e le province autonome di Trento e Bolzano, determinazione 3 marzo 2005)

Aspetti generali e vaccinazioni in uso.

Abadoglu O., Mungan D., Pasaoglu G., Celik G., Misirligil Z. Influenza vaccination in patients with asthma: effect on the frguency of upper respiratory tract infections and exacerbations. J Asthma. 2004 41(3):279-83.

Anderson R.M., May R.M. Immunization and herd immunity. Lancet 1990 335(8690):641-5.

Balinska M.A. Vaccination in tomorrow's society. Lancet Infect Dis. 2003 3(7):443-7. Balinska M.A. What is vaccine advocacy? Proposal for a definition and action. Vaccine. 2004 22(11-12): 1335-42.

Cates C.J., Jefferson T.O., Bara A.I., Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2004 (2):CD000364.

Cavdar C., Sayan M., Sifil A., Artuk C., Yilmaz N., Bahar H., Camsari T. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003 37(1): 71-6.

CDC. Pertussis outbreak among adults at an oil refinery-Illinois, August-October 2002. MMWR 2003 52(1):1-4.

CDC. Recommended Childhood and Adolescent Immunization Schedale -- United States, July-December 2004. MMWR 2004 53(16):Q1-4.

Chen R.T., DeStefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly J.P., Black S.B., Shinefield H.R., Vadheim C.M., Ward J.I., Marcy S.M. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ. 2000 78(2):186-94.

Christy C., Aligne C.A., Auinger P., Pulcino T., Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch Dis Child. 2004 89(8):734-5.

Crovari P., Principi N., Valsecchi M., Biangiardi F., Bonati M., Buzzi E., Carceri V., Cinquetti S., De Stefano Caraffa D., Garattini S., Giuffrè L., Greco D., Lagravinese D., Lizioli A., Maida A., Romano G. Significato ed evoluzione del ricorso alla «obbligatorieta» nella politica delle vaccinazioni in Italia per gli anni 2000. Tendenze nuove. 1998 2(5):22-34.

Davies P., Nwokoro C., Leigh M. Vaccinations against influenza and pneumococcus in children with diabetes: telephone questionnaire survey. BMJ. 2004 328(7433):203.

De Melker H.E., Schellekens J.F., Neppelenbroek S.E., Mooi F.R., Rumke H.C., Conyn-van Spaendonck M.A. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000 6(4):348-57.

Demicheli V., Rivetti D., Deeks J., Jefferson T. Vaccines for preventing influenza in healtly adults. Cochrane Database Syst Rev. 2004 3:CD001269.

Diekema D.S., Marcuse E. Problemi etici nella vaccinazione dei bambini, in Le vaccinazioni: cap. 2, pag. 17-26.

Ehreth J. The value of vaccination: a global perspective. Vaccine. 2003 21 (27-30):4105-17.

Esposito S., Faldella G., Giammanco A., Bosis S., Friscia O., Clerici M., Principi N. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002 20(23-24):2928-32.

Gallo G., Ciofi degli Atti M.L., Cerquetti M., Piovesan C., Tozzi A.E., Salmaso S. Impact of a regional Hib vaccination programme in Italy. Vaccine. 2002 20(7-8):993-5.

Garner D., Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet. 2003 361(9355):395-6.

Gilbertson D.T., Unruh M., McBean A.M., Kausz A.T., Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stae renal disease. Kidney Int. 2003 63(2):738-43.

Gorse G.J., OConnor T.Z., Newman F.K., Mandava M.D., Mendelman P.M., Wittes J, Peduzzi P.N. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis. 2004 190(1):11-9.

Harper S.A., Fukuda K., Cox N.J., Bridges C.B., Advisory Committee on Immunization Practices. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003 52(RR-13):1-8.

Harper S.A., Fukuka K., Uyeki T.M., Cox N.J., Bridges C.B.; Center for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2004 53(32):743.

He Q., Viljanen M.K., Nikkari S., Lyytikainen R., Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis. 1994 170(4):873-7. Hovi T. Inactivated poliovirus vaccine and the final stagea of poliovirus eradication. Vaccine. 2001 19(17-19):2268-72.

Mahoney R.T., Pablos-Mendez A., Ramachandran S. The introduction of new vaccines into developing countries. III. The role of intellectual property. Vaccine. 2004 22(5-6):786-92.

Mangtani P., Cumberland P., Hodgson C.R., Roberts J.A., Cutts F.T., Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis. 2004 190(1): 1-10.

Mehta U., Milstien J.B., Duclos P., Folb P.I. Developing a national system for dealing with adverse events following immunization. Bull World Health Organ. 2000 78(2): 170-7.

Pebody R.G., Gay N.J., Hesketh L.M., Vyse A., Morgan-Capner P., Brown D.W., Litton P, Miller E. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine. 2002 20(7-8):1134-40.

Progress in development of immunization registries -- United States, 2000. MMWR Morb Mortal Wkly Rep. 2001 50(1):3-7.

Ranganathan S., Tasker R., Booy R., Habibi P., Nadel S., Britto J. Pertussis is increasing in unimmunized infants: is a change in policy needed? -- Arch Dis Child. 1999 80(3):297-9.

Roberts K.A., Dixon-Woods M., Fitzpatrick R., Abrams K.R., Jones D.R. Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence. Lancet. 2002 360(9345):1596-9.

Scholtz M., Duclos P. Immunization safety: a global priority. Bull World Health Organ. 2000 78(2):153-4.

Smith S.A., Poland G.A.; American Diabetes Association. Influenza and pneumococcal immunization in diabetes. Diabetes Care. 2004 27 Suppl 1:S111-3.

Spier R.E. Prophylaxis: the foundation for our future progress. Vaccine. 1992 10(14):971-6.

Steinhoff M., Goldblatt D. Conjugate Hib vaccines. Lancet. 2003 361(9355):360-1.

Tacken M.A., Braspenning J.C., Berende A., Hak E., De Bakker D.H., Groenewegen P.P., Grol R.P. Vaccination of high-risk patients against influenza: impact on primary care contact rates during epidemics; Analysis of routinely collected data. Vaccine. 2004 22(23-24):2985-92.

Taranger J., Trollfors B., Knutsson N., Sundh V., Lagergard T., Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine. 1999 18(9-10):884-91.

Turnbull F.M., Heath T.C., Jalaludin B.B., Burgess M.A., Ramalho A.C. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000 19(6):628-36.

Van der Wielen M., Van Damme P., Joossens E., Francois G., Meurice F., Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000 18(20):2075-82.

Van Rie A., Hethcote H.W. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine. 2004 22(23-24):3154-65.

Vilchez R.A., Fung J., Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis. 2002 4(4):177-82.

Von Konig C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002 2(12):744-50.

Where have all the vaccines gone? Lancet Infect Dis. 2004 4(4):187.

Williams J., Goodwin P. Influenza immunisation in children: good for everyone or reserve for the chosen few? Paediatr Respir Rev. 2004 5(1):85-9.

Wolfe R.M., Sharp L.K. Anti-vaccinationists past and present. BMJ. 2002 325(7361):430-2.

World Health Organization Regional Office for Europe. Vaccines immunization and Biologicals, schedule for selected antigen: for selected country. http//www.euro.who.int/vaccine.

Zgibor J.C., Stevenson J.A., Rohay J.M., Perry S.B., Dyer N.J., Freed B. Palevsky P.M. Tracking and improving influenza immunization rates in a high-risk medicare beneficiary population. J Healthc Qual. 2003 25(6):17-24, 27.

Vaccino Pneumococco coniugato.

Bjornson G., Scheifele D., Binder F., Talling D. Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994-1998, Can Commun Dis Rep. 2000 26(18):149-51; discussion 151-2.

Black S.B., Shinefield H.R., Hansen J., Elvin L., Laufer D., Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001 20(12):1105-7.

Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., Noyes J., Lewis E., Ray P., Lee J., Hackell J. Effectiveness of heptavalent pneumococcal coniugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002 21(9):810-5.

Camou T., Palacio R., Di Fabio J.L., Hortal M. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and coniugate vaccine formulations. Vaccine. 2003 21(17-18):2093-6.

Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., Takala A., Kayhty H., Karma P., Kohberger R., Siber G., Makela P.H., Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001 344(6):403-9.

Eskola J., Takala A.K., Kela E., Pekkanen E., Kalliokoski R., Leinonen M. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA. 1992 268(23):3 323-7.

Eskola J., Black S., Shinefield H. Pneumococcal Conjugate Vaccines. In: Vaccines IV Edition (Saunders Ed.). Plotkin SA, Orenstein W.A., Chapter 23; pp.589-624.

Esposito S., Madore D.V., Gironi S., Bosis S., Tosi S., Bianchi C., Cimino C., Principi N. Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community acquired pneumonia in children in Italy. Vaccine. 2003 21(21-22):2704-7.

Jefferson T., Demicheli V. Polysaccharide pneumococcal vaccines. BMJ. 2002 325(7359):292-3.

Kaplan S.L., Mason E.O. Jr, Wald E., Tan T.Q., Schutze G.E., Bradley J.S., Givner L.B., Kim K.S., Yogev R., Barson W.J. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J. 2002 21(2):141-7.

Lee L.H., Frasch C.E., Falk L.A., Klein D.L., Deal C.D. Correlates of immunity for pneumococcal coniugate vaccines. Vaccine. 2003 21(17- 18):2190-6.

Levine O.S., Farley M., Harrison L.H., Lefkowitz L., McGeer A., Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999 103(3):E28.

McIntosh E.D., Conway P., Willingham J., Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine. 2003 21(19-20):2564-72.

MMWR 49(RR-9): 1-35,2000. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP).

OBrien K.L., Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine. 2003 21(17-18):1815-25.

Pelton S.I., Dagan R., Gaines B.M., Klugman K.P., Laufer D., OBrien K., Schmitt H.J. Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine. 2003 21(15):1562-71.

Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., Damaske B., Stefonek K., Barnes B., Patterson J., Zeli E.R., Schuchat A., Whitney C.G.; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the coniugate vaccine era. JAMA. 2001 285(13):1729-35.

Scheifele D., Halperin S., Pelletier L., Talbot J. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis. 2000 31(1):58-64.

Shinefield H., Black S., Ray P., Fireman B., Schwalbe J., Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002 21(3):182-6.

Spoulou V., Gilks C.F., Ioannidis J.P. Protein conjugate pneumococcal vaccines. BMJ. 2002 324(7340):750-1.

Veenhoven R., Bogaert D., Uiterwaal C., Brouwer C., Kiezebrink H., Bruin J., IJzerman E., Hermans P., de Groot R., Zegers B., Kuis W., Rijkers G., Schilder A., Sanders E. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003361(9376):2189-95.

Von Kries R., Siedler A., Schmitt H.J., Reinert R.R. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis. 2000 31(2):482-7. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., Reingold A., Cieslak P.R., Pilishvili T., Jackson D., Facklam R.R., Jorgensen J.H., Schuchat A., Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003 348(18):1737-46.

Zangwill K.M., Greenberg D.P., Chiu C.Y., Mendelman P., Wong V.K., Chang S.J., Partridge S., Ward J.I. Safety and immunogenicity of a heptavalent pneumococcal coniugate vaccine in infants. Vaccine. 2003 21(17-18):1894-900.

Vaccino Meningococco C coniugato.

Achtman M., van der Ende A., Zhu P., Koroleva I.S., Kusecek B., Morelli G., Schuurman I.G., Brieske N., Zurth K., Kostyukova N.N., Platonov A.E. Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. Emerg Infect Dis. 2001 7(3):420-7.

Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002 51(9):717-22.

Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001 69(3):1568-73.

Bose A., Coen P., Tully J., Viner R., Rooy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet. 2003 361(9358):675-6.

Campagne G., Garba A., Fabre P., Schuchat A., Ryall R., Boulanger D., Bybel M., Carlone G., Briantais P., Ivanoff B., Xerri B., Chippaux J.P. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J. 2000 19(2):144-50.

CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000 49:1-10.

Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992 10(10):691-8. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., Achtman M., Densen P., Frasch C.E., Kayhty H., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzymelinked immunosorbent assay. J Clin Microbiol. 1994 32(6):1475-82.

Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969 129(6):1327-48.

Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969 129(6):1385-95.

Granoff D.M., Feavers I.M., Borrow R. Meningococcal Vaccines. In: Vaccines IV Edition (Saunders Ed.). Plotkin S.A., Orenstein W.A., Chapter 34; pp. 959-987.

Jodar L., Cartwright K., Feavers I.M. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals. 2000 28(3): 193-7.

Jodar L., Feavers I.M., Salisbury D., Granoff D.M. Development of vaccines against meningococcal disease. Lancet. 2002 359(9316):1499-508.

Lingappa J.R., Rosenstein N., Zell E.R., Shutt K.A., Schuchat A., Perkins B.A.; Active Bacterial Core surveillance (ABCs) team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001 19(31):4566-75.

Maiden M.C., Stuart J.M.; U.K. Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C coniugate polysaccharide vaccination. Lancet. 2002 359(9320):1829-31.

Miller E., Salisbury D., Ramsay M. Planning, Registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001 20 Suppl l:S58-67.

Morley S.L., Pollard A. J. Vaccine prevention of meningococcal disease, coming soon? Vaccine. 2001 20(5-6):666-87.

Offit P.A., Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet. 2004 364(9431):309-10.

Perez-Trallero E., Vicente D., Montes M., Cisterna R. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet. 2002 360(9337):953.

Pollard A.J., Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001 19(11-12):1327-46.

Ramsay M.E., Andrews N., Kaczmarski E.R., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001 357(9251): 195-6.

Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., Cartwright K., Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001 183(1):160-3.

Richmond P., Goldblatt D., Fusco P.C., Fusco J.D., Heron I., Clark S., Borrow R, Michon F. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 1999 18(7-8):641-6.

Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., Cieslak P., Shutt K.A., Popovic T., Schuchat A., Harrison L.H., Reingold A.L. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999 180(6):1894-901.

Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughea J.M. Meningococcal disease. N Engl J Med 2001 344(18):1378-88.

Ruedin H.J., Ess S., Zimmermann H.P., Szucs T. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine. 2003 21(27-30): 4145-52.

Salmaso S., Mastrantonio P., Scuderi G., Congiu M.E., Stroffolini T., Pompa M.G., Squarcione S. Pattern of bacterial meningitis in Italy, 1994. Eur J Epidemiol. 1997 13(3):317-21.

Shigematsu M., Davison K.L., Charlett A., Crowcroft N.S. National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001. Epidemiol Infect. 2002 129(3):459-70.

Sparling P.F. A plethora of host factors that determine the outcome of meningococcal infection. Am J Med 2002 112(1):72-4.

Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004 364(9431):365-7.

Vaccino Varicella.

Arvin A.M. Varicella vaccine -- the first six years. N Engl J Med. 2001 344(13):1007-9.

Brisson M., Edmunds W.J., Gay N.J., Miller E. Deaths from chickenpox. Deaths from chickenpox in adults are decreasing. BMJ. 2002 324(7337):609.

CDC and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996 45(RR-11): 1-36.

CDC. Simultaneous administration of varicella vaccine and other recommended childhood vaccines -- United States, 1995-1999. MMWR. 2001 50(47):1058-61.

Ciofi degli Atti M.L., Rota M.C., Mandolini D., Bella A., Gabutti G., Crovari P., Salmaso S. Assessment of varicella underreporting in Italy. Epidemiol Infect. 2002 128(3):479-84.

Dworkin M.S., Jennings C.E., Roth-Thomas J., Lang J.E., Stukenberg C., Lumpkin J.R. An Outbreak of Varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis. 2002 35(1):102-4.

Gabutti G., Penna C., Rossi M., Salmaso S., Rata M.C., Bella A., Crovari P.; Serological Study Group. The seroepidemiology of varicella in Italy. Epidemiol Infect. 2001 126(3):433-40.

Galil K., Fair E., Mountcastle N., Britz P., Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis. 2002 186(1):102-5.

Galil K., Lee B., Strine T., Carraher C., Baughman A.L., Eaton M., Montero J., Seward J. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002 347(24): 1909-15.

Gherson A.A., Takahashi M., Jo White C. Varicella Vaccine. In: Vaccines IV Edition (Saunders Ed.). Plotkin SA, Orenstein W.A., Chapter 19; pp. 475-507.

Izurieta H.S., Strebel P.M., Blake P.A. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA. 1997 278(18):1495-9.

Jumaan A.O., Seward J. The effectiveness of the varicella vaccine. N Engl J Med. 2001 345(6):464-5.

MacMahon E., Brown L.J., Bexley S., Snashall D.C., Patel D. Identification of potential candidates far varicella vaccination by history: questionnaire and seroprevalence study. BMJ. 2004 329(7465):55 1-2.

Noah N. Adults still account far many deaths from chickenpox. BMJ. 2002 325(7357):221.

Rawson H., Crampin A., Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis ofroutine mortality data. BMJ. 2001 323(7321):1091-3.

Thiry N., Beutels P., Tancredi F., Romano L., Zanetti A., Bonanni P., Gabutti G., Damme P.V. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine. 2004 22(27-28):3546-62.

Vazquez M., La Russa P.S., Gershon A.A., Steinberg S.P., Freudigman K., Shapiro E.D. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001 344(13):955-60.

Vaccino Pneumococcico polisaccaridico.

Bartlett J.G. Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995;333:1618-24 Buttler J.C., Breiman R.F., Campbell J.K., Lipman H.B., Broome C.V., Facklam RR. Pneumococcal polyvalent vaccine efficacy: An evaluation of current recommendations. JAMA 1993 270:1826-31.

CDC. Pneumococcal vaccination for cochlear imelant candidates and recipients: updated recommendations of the advisory Committee on Immunization Practices. MMWR 2003 52:739-40.

CDC. Prevention of Pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(RR-8).

Christenson B., Hedlund J., Lundbergh P., Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004 23(3):363-8.

Christenson B., Lundbergh P., Hedlund J., Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001 357(9261):1008-11.

Conaty S., Watson L., Dinnes J., Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomized controlled trials. Vaccine. 2004 22(23-24):3214-24.

Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials: Vaccine 2001 19:4780-90.

D'Alessandro D., Bevilacqua M., Carreri V., Ciriminna S., Crovari P., De Stefano Caraffa D., Faggioli A., Fara G.M., Ferro A., Greco D., Grilli G., Lizioli A., Navarra M., Pantosti A., Pompa M.G., Ragni P., Roveri P., Salmaso S., Todisco T. The Working Group on the Prevention of S. pneumoniae Infections in Italy. The final report. Ann Ig. 1999 11(4):341-50.

Farr B.M., Johnson B.M., Cobb DK, Fisch M.J., Germanson T.P., Adal K.A. et al. Preventing pneumococcal bacteremia in patient at risk. Results of a matched case-control study. Arch Int Med 1995;155:2336-40.

Fedson D.S. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. Lancet Infect Dis 2003 3:272-4.

Fine M.J., Smith M.A., Carson C.A., Meffe F., Sankey S.S., Weissfeld L.A. et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994 154:2666-77.

French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J Infect. 2003 46(2):78-86.

Hedlund J., Christenson B., Lundbergh P., Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine 2003 21:3906-11.

Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., Hanson C.A., Mahoney L.D., Shay D.K., Thompson W.W.; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003 348(18):1747-55.

Kaplan V., Angus D.C., Griffin M.F., Clermont G., Scott Watson R., Linde-Zwirble W.T. Hospitalized community acquired pneumonia in the elderly: age and sex related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002 165:766-72.

Mangtani P., Cutts P., Hall A.J. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of evidence. Lancet Infect Dis 2003 3:71-8.

Marston B.J., Plouffe J.F., File T.M. Jr. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997 157:1709-18.

Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal vaccines effective? Meta analysis of the prospective trials. BMC Family Practice 2000 1:1.

Moro M.L., Pantosti A., Boccia D.; Gruppo EARSS-Italia. Antibiotic microbial resistance surveillance in invasive infections caused by Streptococcus pneumoniae and Staphylococcus aureus: the EARSS (European Antimicrobial Resistance Surveillance System) project in Italy (April 1999-April 2000). Ann Ig. 2002-14(5):361-71.

Nichol K.L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999 159:2437-42.

Porath A., Schlaeffer F., Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J. Infect 1997 34:41-[26].

Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C. et al. Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001 285:1729-35.

Straetemans M., Sanders E.A., Veenhoven R.H., Schilder A.G., Damoiseaux R.A., Zielhuis G.A. Review of randomized trials on pneumococcal vaccination for prevention of otitis media. Pediatr Infect Dis 2003 22:515-24.

Wagner C., Popp W., Posch M., Vlasich C., Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003 49:246-50.

Watson L., Wilson B.J., Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002 20:2166-73.

Weaver M., Krieger J., Castorina J., Walls M., Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med. 2001 161(1):111-20.

Wuorimaa T., Kayhty H. Current state of pneumococcal vaccines. Scand J. Immunol. 2002 56(2):111-29.

Zimmerman R.K., Santibanez T.A., Fine M.J., Janosky J.E., Nowalk M.P., Bardella I.J., Raymund M., Wilson S.A. Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine. 2003 21(13-14):1510-7.